Governor Healey's budget would cut co‑responder funding by roughly $15 million, drawing sharp criticism from police chiefs and mental‑health advocates. Supporters warn the move could mean more arrests and ER visits.

A Canoga Park payment processor was sentenced in Boston after prosecutors said the firm handled payments for online pharmacies selling counterfeit "Adderall." Tests found methamphetamine in some pills.

Mostly sunny and blustery this afternoon with a high near 48°F. Rain likely Sunday night and a chance of wet snow Monday.

A Marshfield man was arrested after a hidden recorder was found in a unisex bathroom at Cohasset’s Paul Pratt Library. Police say forensic analysis uncovered video and audio of restroom users.

A crowded Democratic primary to replace Seth Moulton is shaping into a test between well‑connected insiders and local outsiders. Dan Koh’s early money and endorsements have reshaped the field.

An Oak Bluffs babysitter is awaiting trial after a two‑year‑old’s death; the child’s father told local TV he believed the caregiver ‘tortured’ his son as criminal and civil cases proceed.

Pop-up bar 261 has opened at the Envoy Hotel, centering screens on women's sports and honoring Kathrine Switzer's 261 bib.

The City Council approved a $2.1M free‑cash transfer to cover police and fire pay and urged the mayor to freeze new overtime requests amid FY26 budget pressures.

A 16-year-old from Needham faces murder and gun charges after the Oct. 13, 2025 fatal shooting of Marie Molea-Anthony in Roxbury.

Northpoint Bible College appealed after its accreditor initiated an adverse‑action notice; an appeal hearing is set by May 15, 2026, and students face possible federal‑aid impacts.

Six Manchester residents were arraigned after prosecutors say they chased and beat a 19‑year‑old at Downtown Crossing and stole his phone.

More than 160 Harvard Club employees in Back Bay voted to join UFCW Local 1445 after a March NLRB election, citing low pay and no contract since June 2024.

Aldeyra’s shares plunged about 70% after the FDA declined to approve reproxalap, the Lexington biotech’s lead dry‑eye candidate.